A Descriptive Retrospective Database Study to Evaluate Serious Clinical Manifestations and Outcomes among SARS-CoV-2 Diagnosed Patients with RA, PsA or UC treated with systemic therapies: A Post Approval Safety Study of Tofacitinib in the Context of the COVID-19 Pandemic

29/05/2020
22/02/2024
EU PAS number:
EUPAS35384
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

A3921380_PROTOCOL and APPROVAL_COVID PASS_15May2020

English (2.4 MB - PDF) View document
Updated protocol

A3921380_Protocol Amendment 2 Version 3.0 (clean)_COVID PASS_28 August 2023_Redacted

First published: 22/02/2024
English (3.6 MB - PDF) View document
Study results
Study results

A3921380 Non Interventional Study Report Abstract 21 June 2023_Redacted

English (1.27 MB - PDF) View document
Study report
Other information
Study, other information

A3921380 Non Interventional Study Report 11 September 2023_Pages 51-97 Redacted

English (5.34 MB - PDF) View document

A3921380 Non-Interventional Protocol Abstract 12 May 2020

English (1.75 MB - PDF) View document

A3921380_Protocol Amendment 1 (clean)_COVID PASS_20 July 2021

English (2.37 MB - PDF) View document